Global Wilson’s Disease Market: Industry Analysis & Outlook (2016-2020) Koncept Analytics

View Report Details Global Wilson’s Disease Market: Industry Analysis & Outlook ---------------------------------------(2016-2020)

View Report Details Executive Summary 

Wilson’s disease is a rare disease and is named after Kinnear Wilson who was the first to describe this disorder in 1912.

His description terms the disease as a “progressive lenticular degeneration,” a hereditary, fatal neurological disease that is usually accompanied by chronic liver ailment that leads to a condition called cirrhosis. Wilson's disease is a hereditary disorder that leads to unwarranted accumulation of copper in crucial organs such as the liver, brain etc. The patient starts to accumulate copper from birth but diagnosis tends not to occur only in the later ages. The primary signs of Wilson’s disease become prominent usually between the ages of 12 and 23 years.



Wilson’s disease is caused by the mutation of a gene named ATP7B. Absent or reduced function of ATP7B protein leads to reduced elimination of copper into the bile. Wilson’s disease is inherited as an autosomal recessive trait, which means that in order to develop the disease one must inherit two procreations of the defective gene, one from each parent. If a person receives only one abnormal gene from either of the parents, he/she is not likely to get affected by the Wilson’s disease.

Wilson’s disease may be difficult to primarily diagnose as the symptoms are alike to other health issues like heavy metal poisoning, hepatitis C, and cerebral palsy.



The important factors that are anticipated to drive the market include rising prices of chelators in the US, rising attractiveness of orphan drugs market, increasing global healthcare expenditure as well as spending on medicines. The noteworthy trends in the market include falling number of prescriptions for Wilson’s disease, and the development of gene therapy as a potential cure for the disease. However, the market is confronted by crucial challenges such as underdiagnosis of the disease, lack of safety in treatments, poor compliance to current treatments and unmet efficacy needs.



This report provides a wide-ranging study of global Wilson’s disease market and also its key regional markets such as the US and Europe. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global Wilson’s disease industry is highly competitive consisting of several large corporations. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

Though it is known that Wilson’s disease is a rare condition, the prevalence of this disease is limited also because the occurrence of this condition is highly underdiagnosed…

Global Orphan Drugs Market Revenue – Actuals (2012-2015)

Wilson’s Disease Prevalence by Region (2015)

•

The global orphan drugs market revenue has been growing at a CAGR of xx% during the period spanning 2012-2015. For the year 2015, the global orphan drugs revenue was noted to be US$... billion which has increased from US$.. billion in the year 2014.

•

It is noted that the prevalence of Wilson’s disease is the largest in Europe with nearly … persons being affected by it in the year 2015, followed by the US with …. persons affected by Wilson’s disease.

•

In terms of treatment among newly diagnosed patients, it is noted that the market remains highly skewed towards D-penicillamine, which recorded a share of xx% of the total market in the year 2015

Wilson’s Disease Market by Treatment – New Patients (2015)

Europe has the highest prevalence of Wilson’s disease in the world…

Europe Wilson’s Disease Prevalence – Forecast (2015-2020)

Europe Wilson’s Disease Market by Treatment (2015)

•

The number of persons affected with Wilson’s disease in Europe in the year 2015, was noted to be …… persons. It is forecasted that the prevalence count will reach a sum of ….. persons by the end of the year 2020.

•

It is noted that in the year 2015, zinc salts constituted xx% of the total market while chelators constituted nearly xx% of the total market in the same period.

•

The number of Wilson’s disease patients treated with zinc in the year 2015 is noted to be …. persons. It is forecasted that the number of patients treated with zinc will rise at a CAGR of xx% over the period 2015-2020, attaining a total of …. persons by the end of the year 2020.

Europe Wilson’s Disease Patients Treated with Zinc - Forecast (2015-2020)

Even though the number of prescriptions for chelators has been declining over the past few years in the US, the continuing rise in the prices of chelators is set to make the market revenue grow over the forthcoming years…

The US Wilson’s Disease Prevalence – Forecast (2015-2020) • The prevalence of Wilson’s disease is the second largest in the US with nearly … persons affected by it in the year 2015. It is forecasted that the prevalence of this disease will grow rather gradually at a CAGR of xx% over the forthcoming period spanning 2015-2020.

• It is forecasted that the market revenue of copper chelators for Wilson’s disease in the US will grow at a CAGR of xx% over the period spanning 2016-2020, attaining total revenue of US$.... million by the end of 2020.

• The total number of patients treated with chelators in 2015, was recorded to be ….. persons in the US. It is forecasted that the number of patients treated with chelators will attain a sum of …. persons by the end of 2020.

The US Chelators Market Revenue – Forecast (2016-2020)

The US Wilson’s Disease Patients Treated with Chelators – Forecast (2015-2020)

Contact Us: View Report Details These are abridged and sanitized sample pages from the comprehensive report on the “ Global Wilson Disease Market ”. To know more about this report or for any customized research requirement, please contact the following:

Koncept Analytics

Vikas Gupta BD Manager

CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com

www.konceptanalytics.com